Technology Strategy Board – Smart Funding Award

Press Release For Immediate Release Oval Medical awarded Technology Strategy Board Smart funding award Cambridge, UK. 14 April 2014 – Oval Medical Technologies Limited (“Oval”) announced today they have received a Smart funding award from the UK’s innovation agency, the Technology Strategy Board, of £228,256 for a project that will progress the development of the […]

Continue Reading 0

Oval Medical announces new Chairman of the Board

Oval Medical Technologies Limited (“Oval”), a leading auto-injector company, has named Dr. Paul Harper as Chairman of the Board. He will be succeeding Peter Keen after his three-year tenure.  Peter has now taken the position of Chief Executive at investment fund Cambridge Innovation Capital. Dr Harper took up the role at Oval in January 2014, […]

Continue Reading

Oval Medical secures £1 million deal with US pharmaceutical company

Oval Medical Technologies Ltd (‘Oval’) today announced that they have signed another deal following an initial feasibility study with a global pharmaceutical company, to a value in excess of one million pounds. The feasibility study, which primarily focused on the pharmaceutical drug’s stability in Oval’s standard primary drug container, started in March 2012 and completed […]

Continue Reading

Oval Medical appoints new CEO

The board of Oval Medical Technologies Limited (‘Oval’) announces that effective from 1st May 2013, Barbara Lead has succeeded Dr Catherine Beech as Chief Executive Officer of Oval Medical Technologies Limited. Catherine was instrumental in establishing Oval with Matthew Young in late 2009 and completing the initial Angel financing in early 2010. Since then, with […]

Continue Reading

Oval Medical announces the availability of functional prototypes

30th May 2013 – Oval Medical Technologies Ltd (‘Oval’), today have announced that functional prototypes of their autoinjector technology are now available. Oval’s specification for a standard 1ml device was clearly met by delivering 1ml of drug subcutaneously, through a 27G needle in less than 7 seconds. The fully functional injection-moulded prototypes demonstrate the simplicity […]

Continue Reading

Revolutionary autoinjector pushes the limits of high viscosity drug delivery

17th April 2013 – Oval Medical Technologies Ltd (‘Oval’), today have announced that a variety of 1100 cPs solutions (the thickness of motor oil) have been successfully delivered through a 25G thin wall needle, in less than 7 seconds, using their revolutionary autoinjector. Oval is a cutting-edge autoinjector company based in Cambridge UK. Their autoinjector […]

Continue Reading

Oval Medical receives ISO 13485:2012 certification for medical device development

21st February 2013 – Oval Medical Technologies Ltd (‘Oval’), the privately held autoinjector development company, today announced that is has been awarded BS EN ISO 13485:2012 certification. ISO 13485 is a quality standard certifying that the company has a comprehensive management system in place for the design, development and manufacture of drug delivery devices. This […]

Continue Reading

Oval Medical Technologies signs key agreement with leading global pharmaceutical company

May 14th, 2012 – Oval Medical Technologies Ltd. (“Oval”), the company developing the next generation of autoinjectors, today announced that they have entered into an agreement with a top ten global pharmaceutical company to evaluate one of their leading prescription drugs in Oval’s novel autoinjector technology. Under the terms of Agreement, the pharmaceutical company has […]

Continue Reading